Utomilumab (PF 05082566) 是一种人源化的 IgG2 mAb 激动剂，靶向T 细胞共刺激受体4-1BB/CD137。Utomilumab 可用于复发/难治性滤泡性淋巴瘤 (FL) 和其他 CD20+非霍奇金淋巴瘤 (NHL) 的研究。
| 生物活性 | Utomilumab (PF 05082566) is a fully humanIgG2mAb agonist of the T-cell costimulatory receptor4-1BB/CD137. Utomilumab can be used for the research of relapsed/refractory follicular lymphoma (FL) and otherCD20+non-Hodgkin lymphomas (NHL)[1][2]. |
| IC50& Target | |
| Clinical Trial | |
| 分子量 | |
| 性状 | |
| Formula | |
| CAS 号 | |
| 运输条件 | Room temperature in continental US; may vary elsewhere. |
| 储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. |
